We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche Antiviral Drug Reduces Transmission in Late-stage Study
Read MoreHide Full Article
Roche (RHHBY - Free Report) announced positive top-line results from a late-study on influenza drug, Xofluza.
The CENTERSTONE study was a global phase III trial investigating the efficacy of single-dose Xofluza, taken within 48 hours of the symptoms’ onset, to reduce the transmission of influenza within households.
Xofluza is approved in several countries for the treatment of uncomplicated influenza types A and B.
Year to date, Roche’s shares have risen 9% compared with the industry’s 24.8% growth.
Image Source: Zacks Investment Research
Roche’s Xolfuza Reduces Transmission
The CENTERSTONE study met its primary endpoint. Data showed that a single, oral dose of Xofluza taken by people infected with influenza significantly reduced the likelihood of others in their household contracting the virus.
The drug was well tolerated with no new safety signal identified.
Per Roche, this study is the first global phase III study to show a transmission reduction benefit with an antiviral used in the treatment of a respiratory viral illness. The study was conducted in more than 4,000 participants.
This new positive data should add to the benefits of Xofluza, which is presently approved for treating symptoms and preventing infection following virus exposure.
The CENTERSTONE study has been partially supported with funds from the U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, and Biomedical Advanced Research and Development Authority.
Xofluza’s ability to reduce the spread of infection could help limit transmission within communities and societies. Its mechanism of action has demonstrated efficacy in a wide range of influenza viruses, including vitro activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies.
Roche’s Broad Portfolio
Apart from Xofluza, Roche has another flu drug, named Tamiflu, in its portfolio.
Roche’s year-to-date performance has been impressive on high demand for its drugs and tests. Vabysmo (eye diseases) was the biggest growth driver of sales, with Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Evrysdi (spinal muscular atrophy) being the other significant contributors.
Ophthalmology drug Vabysmo continues its stellar performance. The drug has grabbed market share from Regeneron’s market-leading drug Eylea. Positive data from additional studies bode well for the drug.
Meanwhile, Roche is also looking to diversify and broaden its portfolio in the wake of declining sales from legacy drugs due to competition from biosimilars.
Estimates for Eli Lilly’s 2024 earnings have risen from $15.77 to $16.49 per share over the past 30 days. For 2025, the bottom-line estimate has risen from $22.79 to $23.97 over the same time frame. Year to date, Lilly’s shares have risen 58.4%.
Estimates for BAYRY’s 2024 earnings have risen from $1.35 to $1.38 per share over the past 60 days. For 2025, the bottom-line estimate has risen from $1.42 to $1.44 over the same time frame.
Estimates for PFE’s 2024 earnings have risen from $2.39 to $2.62 per share over the past 60 days. For 2025, the bottom-line estimate has risen from $2.75 to $2.85 over the same time frame.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Roche Antiviral Drug Reduces Transmission in Late-stage Study
Roche (RHHBY - Free Report) announced positive top-line results from a late-study on influenza drug, Xofluza.
The CENTERSTONE study was a global phase III trial investigating the efficacy of single-dose Xofluza, taken within 48 hours of the symptoms’ onset, to reduce the transmission of influenza within households.
Xofluza is approved in several countries for the treatment of uncomplicated influenza types A and B.
Year to date, Roche’s shares have risen 9% compared with the industry’s 24.8% growth.
Image Source: Zacks Investment Research
Roche’s Xolfuza Reduces Transmission
The CENTERSTONE study met its primary endpoint. Data showed that a single, oral dose of Xofluza taken by people infected with influenza significantly reduced the likelihood of others in their household contracting the virus.
The drug was well tolerated with no new safety signal identified.
Per Roche, this study is the first global phase III study to show a transmission reduction benefit with an antiviral used in the treatment of a respiratory viral illness. The study was conducted in more than 4,000 participants.
This new positive data should add to the benefits of Xofluza, which is presently approved for treating symptoms and preventing infection following virus exposure.
The CENTERSTONE study has been partially supported with funds from the U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, and Biomedical Advanced Research and Development Authority.
Xofluza’s ability to reduce the spread of infection could help limit transmission within communities and societies. Its mechanism of action has demonstrated efficacy in a wide range of influenza viruses, including vitro activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies.
Roche’s Broad Portfolio
Apart from Xofluza, Roche has another flu drug, named Tamiflu, in its portfolio.
Roche’s year-to-date performance has been impressive on high demand for its drugs and tests. Vabysmo (eye diseases) was the biggest growth driver of sales, with Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Evrysdi (spinal muscular atrophy) being the other significant contributors.
Ophthalmology drug Vabysmo continues its stellar performance. The drug has grabbed market share from Regeneron’s market-leading drug Eylea. Positive data from additional studies bode well for the drug.
Meanwhile, Roche is also looking to diversify and broaden its portfolio in the wake of declining sales from legacy drugs due to competition from biosimilars.
Roche’s Zacks Rank & Key Picks
Roche currently carries a Zacks Rank # 3 (Hold).
Some better-ranked stocks from the large-cap pharma industry are Eli Lilly (LLY - Free Report) , Bayer (BAYRY - Free Report) and Pfizer (PFE - Free Report) . While LLY sports a Zacks Rank #1 (Strong Buy) at present, BAYRY and PFE carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Eli Lilly’s 2024 earnings have risen from $15.77 to $16.49 per share over the past 30 days. For 2025, the bottom-line estimate has risen from $22.79 to $23.97 over the same time frame. Year to date, Lilly’s shares have risen 58.4%.
Estimates for BAYRY’s 2024 earnings have risen from $1.35 to $1.38 per share over the past 60 days. For 2025, the bottom-line estimate has risen from $1.42 to $1.44 over the same time frame.
Estimates for PFE’s 2024 earnings have risen from $2.39 to $2.62 per share over the past 60 days. For 2025, the bottom-line estimate has risen from $2.75 to $2.85 over the same time frame.